Amicus Therapeutics Stock News

Amicus Therapeutics Inc. (NASDAQ:FOLD) has a beta value of 1.21 and has seen 1.25 million shares traded in the last trading session. The company, currently valued at $3.03B, closed the last trade at $10.80 per share which meant it lost -$0.54 on the day or -4.76% during that session. The FOLD stock price is -135.09% Amicus Therapeutics Inc. (FOLD) Has A Bright Growth Prospects For 2021 Read More »

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T.

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annu

Wall Street brokerages forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will report sales of $86.21 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The lowest sales estimate is $84.66 million and the highest is $87.56 million. Amicus Therapeutics reported sales of $70.57 million during the […]

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabo

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.

Squarepoint Ops LLC trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 94.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,299 shares of the biopharmaceutical companys stock after selling 500,312 shares during the quarter. Squarepoint Ops LLCs holdings in Amicus []

Price T Rowe Associates Inc. MD grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 23.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,567,676 shares of the biopharmaceutical companys stock after purchasing an additional 482,004 shares during the quarter. Price []

Schonfeld Strategic Advisors LLC lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 73.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,300 shares of the biopharmaceutical companys stock after selling 33,804 shares during the quarter. Schonfeld Strategic Advisors LLCs []

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by investment analysts at Stifel Nicolaus from a hold rating to a buy rating in a research report issued to clients and investors on Monday, The Fly reports. Other equities analysts also recently issued reports about the stock. BTIG Research initiated coverage on shares of Amicus Therapeutics in a report []

Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2021 Results - Earnings Call Transcript

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin

It has been a rocky year for Amicus Therapeutics, Inc. (NASDAQ:FOLD), after the stock suffered a dramatic bear gap back in February that it hasn't even come close to recovering from.